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Adenovirus Types 4 and 7 (Ad4 and Ad7) are associated with acute respiratory distress (ARD). In order to prevent widespread Ad-associated ARD (Ad-ARD) the United States military immunizes new recruits using a safe and effective lyophilized wildtype Ad4 and Ad7 delivered orally in an enteric-coated capsule. We cloned Ad4 and Ad7 and modified them
to express either a GFP-Luciferase (GFPLuc) fusion gene or a centralized influenza H1 hemagglutinin (HA1-con). BALB/c
mice were injected with GFPLuc expressing viruses intramuscularly (i.m.) and intranasally (i.n.). Ad4 induced significantly
higher luciferase expression levels as compared with Ad7 by both routes. Ad7 transduction was restored using a human
CD46+ transgenic mouse model. Mice immunized with serial dilutions of viruses expressing the HA1-con influenza vaccine gene were challenged with 100 MLD50 of influenza virus. Ad4 protected BALB/c mice at a lower dose by i.m. immunization as compared with Ad7. Unexpectedly, there was no difference in protection by i.n. immunization. Although Ad7
i.m. transduction was restored in CD46+ transgenic mice, protection against influenza challenge required even higher
doses as compared with the BALB/c mice. However, Ad7 i.n. immunized CD46+ transgenic mice were better protected as
compared with Ad4. Interestingly, the restoration of Ad7 transduction in CD46+ mice did not increase vaccine efficacy
and indicates that Ad7 may transduce a different subset of cells through alternative receptors in the absence of CD46.
These data indicate that both Ad4 and Ad7 can effectively induce anti-H1N1 immunity against a heterologous challenge
using a centralized H1 gene. Future studies in non-human primates or human clinical trials will determine the overall
effectiveness of Ad4 and Ad7 as vaccines for influenza.

Introduction
Adenovirus types 4 and 7 (Ad4 and Ad7) are the primary
causative infectious agents in acute respiratory distress (ARD)
in military recruits during basic training.1 Typically, Ad-ARD
is associated with fever, rhinorrhea, pharyngitis, headache, and
lethargy that is self-limiting and usually resolved in 3 to 10 d.
While Ad-ARD rarely results in death and about 10% of patients
develop pneumonia, the major impact of Ad-ARD is the loss of
training time. Ad-ARD spreads rapidly and has been shown to
affect up to 80% of recruits within a confined military training
facility resulting in 20% of patients requiring hospitalization.2-4
Since 1971, millions of military recruits have been vaccinated
against Ad4 and Ad7 using an orally delivered lyophilized wildtype virus.5 This vaccine has been found to be safe and effective.6,7
The vaccine used by the military was so effective at reducing the
rates of respiratory febrile illness that officials opted to suspend
the vaccine program. Once the vaccine program was halted, cases
of Ad4 and Ad7 associated respiratory illnesses began to increase
and, in 2001, efforts to restore the vaccine program were initiated. Over the past 10 y, the US military has invested ~$100
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million to fully restore vaccine production and vaccination of
military recruits in 2011.7 Ad-ARD cases declined rapidly upon
the restoration of this vaccine program.
Adenovirus Type 5 (Ad5) has been shown to be a very effective viral vector for use in vaccine studies.8-13 However, There are
very high levels of pre-existing immunity to Ad5 in all populations.14-16 In many populations the pre-existing immunity is
100% by the age of 2.14 Therefore, Ad5 seroprevalence is a fundamental problem that is inhibitory to the use of Ad5 as a vaccine
vector in adult humans. A study of 303 military basic trainees
indicated that Ad4 and Ad7 levels of seroprevalence were 34%
and 27%, respectively. Therefore, 89% of these recruits would
be susceptible to vaccination with at least 1 of the 2 Ad4 or Ad7
vaccines.17 Ad4 and Ad7 have been studied as vaccine vectors for
several infectious diseases such as HIV, Hepatitis B, respiratory
syncytial virus (RSV) and, most recently, bird flu (H5N1).6,18-22
As Ad4 and Ad7 are the only 2 adenoviruses ever used as vaccines
in humans to prevent Ad4 and Ad7 ARD, they are very attractive as vaccine vectors for the inclusion of secondary pathogen
genes. Military recruits are vaccinated or boosted against several other pathogens with traditional vaccines.23 However, some
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130277/
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Figure 1. In vivo transduction of Ad4 and Ad7 vectors. Ad4 and Ad7
viruses expressing a GFPLuc fusion gene were used to immunize mice
by intramuscular and intranasal routes and imaged for luciferase activity
24 h later. In vivo transduction and luciferase expression in BALB/c mice
is shown (A). Intramuscular transduction of Ad7 was restored in CD46+
transgenic mice and compared with a standard replication-defective
Ad5 vector expressing the same transgene (B). The sum lumenescence
was determined using the lumazone analysis software and levels were
compared using a 2-tailed T-Test (C). Error bars indicate standard error.

recruits will be vaccinated against pathogens such as smallpox
and anthrax. Vaccines for these pathogens are considered dangerous or require multiple immunizations with annual boosters.23 In
this study we show that these viral vectors are capable of inducing anti-H1N1 influenza immune responses. We hope that these
data, in combination with vaccine studies from other groups, will
result in the design of a multivalent vaccine platform.

Results
In vivo transduction of viral vectors
BALB/c mice were immunized with Ad4 and Ad7 viral vectors expressing the GFPLuc gene and imaged 24 h. later. By
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intramuscular immunization, the Ad4 viral vector induced significantly higher levels of luciferase activity as compared with the
Ad7 viral vector (P = 0.02) (Fig. 1). By the intranasal route, the
Ad4 viral vector also induced significantly higher levels of luciferase activity as compared with Ad7 (P = 0.01) (Fig. 1). However,
when CD46+ transgenic mice were immunized intramuscularly
with the Ad7 viral vector, luciferase activity was restored to levels
equivalent to that of Ad4 in BALB/c mice (Fig. 1B and C). A
commonly used Ad5 replication-defective viral vector was used as
a comparator. Ad4 and Ad7 also induced higher luciferase levels
as compared with the Ad5 vector (P = 0.04 and P = 0.06, respectively) (Fig. 1B and C). Interestingly, the Ad4-GFPLuc viral vector appeared to migrate from the intramuscular injection site to
the liver as detected by imaging. This may be an indicator of the
liver tropic properties of adenoviruses that use the coxsackie and
adenovirus receptor (CAR) for transduction.
Protection by systemic intramuscular immunization in
BALB/c mice
Groups of 5 female BALB/c mice were immunized intramuscularly with serial 10-fold dilutions of Ad4 and Ad7 vaccine vectors expressing a centralized H1 hemagglutinin gene, HA1-con.
Three weeks post-immunization, the mice were challenged with
100 MLD50 of influenza A/PR/8/34. Mice immunized with Ad4
at a dose as low as 109 vp/mouse showed reduced disease and
weight loss (Fig. 2A). Immunization with 109 vp/mouse of Ad4
vaccine also protected 100% of mice from death due to a lethal
challenge of influenza virus (Fig. 2B). In contrast, 1010 vp/mouse
of Ad7 vaccine was required to reduce weight loss in influenza
virus challenged BALB/c mice (Fig. 2C). Intramuscular vaccination with Ad7 required a 10-fold higher concentration (1010 vp/
mouse) to completely protect mice from death as compared with
the Ad4 vaccine (Fig. 2D).
Protection by mucosal intranasal immunization in BALB/c
mice
Groups of 5 female BALB/c mice were immunized intranasally with serial 10-fold dilutions of Ad4 and Ad7 vaccine vectors
expressing HA1-con. Three weeks post-immunization, the mice
were challenged with 100 MLD50 of influenza A/PR/8/34. By
this route and in this mouse model, there were no differences
in vaccine efficacy by either Ad4 or Ad7 (Fig. 3). However, the
dose required to completely protect mice from death was 10-fold
higher by the intranasal route as compared with the intramuscular route (Fig. 3A and B). Interestingly, the Ad7 mice immunized with 1010 vp/mouse did not lose any weight and showed no
signs of disease or death (Fig. 3C and D). In fact, mice immunized with this dose by the i.m. route showed > 10% weight loss,
whereas, mice immunized i.n. showed an overall weight gain over
the 2 wk after influenza challenge (Fig. 3C).
Protection by systemic intramuscular immunization in
CD46+ transgenic mice
Since CD46 appeared to restore Ad7 transduction, we immunized groups of 5 female CD46+ transgenic mice intramuscularly with serial 10-fold dilutions of Ad4 and Ad7 vaccine vectors
expressing HA1-con. The mice were challenged 3 wk postimmunization with 100 MLD50 of influenza A/PR/8/34. In this
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Figure 2. Protection by systemic intramuscular immunization in BALB/c mice. Groups of 5 female BALB/c mice were immunized intramuscularly with
10-fold serial dilutions of Ad4 or Ad7 expressing the centralized HA1-con hemagglutinin gene. Three weeks after immunization the mice were challenged with 100 MLD50 of mouse-adapted influenza A/PR/8/34. Protection against weight loss and survival induced by the Ad4 vaccine is shown in A and
B, respectively. Protection against weight loss and survival induced by the Ad7 vaccine is shown in C and D, respectively. Mice that lost 25% of baseline
body weight were humanely euthanized.

mouse model, Ad4 was even less effective at protecting mice from
weight loss (Fig. 4A) and even groups of mice receiving the highest dose of 1010 vp/mouse of Ad4 were not completely protected
from death upon influenza challenge (Fig. 4B). In contrast to the
in vivo luciferase data, the Ad7 vaccine was even less effective at
protecting mice from weight loss and death after a lethal influenza challenge (Fig. C and D). Interestingly, the lowest does of
Ad7 vaccine (108 vp/mouse) resulted in the highest survival rate
of 60% as compared with 20% for the higher doses (Fig. 4D).
Protection by mucosal intranasal immunization in CD46+
transgenic mice
Groups of 5 female CD46+ transgenic mice were immunized
intranasally with serial 10-fold dilutions of Ad4 and Ad7 vaccine
vectors expressing HA1-con and challenged 3 wk post-immunization with 100 MLD50 of influenza A/PR/8/34. Ad4 induced
lower levels of protection by this route as compared with the
i.m. route. Even the highest i.n. dose of Ad4 vaccine was unable
to completely protect CD46+ mice from weight loss and death
(Fig. 5A and B). Vaccination of mice with 1010 vp/mouse of Ad4
vaccine resulted in only 60% survival (Fig. 5B). Ad7 immunized
CD46+ mice had a delayed weight loss as compared with the Ad4
immunized mice (Fig. 5C). However, all doses of Ad7 resulted in
death after influenza challenge (Fig. 5D). Interestingly, the intermediate (109) and low (108) doses of Ad7 vaccine induced greater
levels of survival as compared with the Ad4 vaccine.
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Discussion
There is a definite need to improve our current vaccine technologies. Here we report the cloning of Ad4 and Ad7 into single
low copy plasmids. These plasmids allow for the ability to rapidly create and modify the genomes to act as vaccine vectors. We
deleted the E3 genes of both Ad4 and Ad7 and replaced them
with CMV-transgene cassettes that expressed either a GFPLuc
or a centralized H1 hemagglutinin (HA1-con). We then tested
these viral vectors to transduce BALB/c and CD46+ transgenic
mice and to induce anti-influenza immunity. While both vectors were capable of inducing protection against a heterologous
influenza A/PR/8/34 lethal virus challenge, the dose required
to induce protection was higher than previously observed using
a replication-defective Ad5 (RD-Ad) vectored vaccine.11 In order
to determine if the levels of protein expression were equivalent
in both Ad4 and Ad7 vaccines, we evaluated GFP and luciferase expression in vitro. We found that Ad4 and Ad7 viruses had
similar virus particle to infectious unit ratios of 103.6 and 95.1,
respectively (Fig. S1A). In addition, there were no significant
differences in luciferase activity expressed by either Ad4 or Ad7
(Fig. S1B). While these data do not represent the actual vaccine
gene (HA1-con) expression, they do indicate that, at least in
the context of these expression cassettes, it may be inferred that
HA1-con expression levels are equivalent.
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Figure 3. Protection by mucosal intranasal immunization in BALB/c mice. Groups of 5 female BALB/c mice were immunized intranasally with 10-fold
serial dilutions of Ad4 or Ad7 expressing the centralized HA1-con hemagglutinin gene. Three weeks after immunization the mice were challenged with
100 MLD50 of mouse-adapted influenza A/PR/8/34. Protection against weight loss and survival induced by the Ad4 vaccine is shown in A and B, respectively. Protection against weight loss and survival induced by the Ad7 vaccine is shown in C and D, respectively. Mice that lost 25% of baseline body
weight were humanely euthanized.

Since the Ad4 and Ad7 viral vaccines were replication-competent (RC-Ad) they may have induced changes to the Th1/Th2
balance, T-regulatory responses, or inflammatory cytokine profiles as compared the RD-Ad vector. The E3 genes play a significant role in immunoevasion and immunomodulation during Ad
infections.24-26 The deletion of the E3 genes without the deletion
of the E1 genes may have impaired this vector as a vaccine, at
least in mice. The anti-Ad4 and Ad7 immune responses generated in the mice by the E3 deleted vectors may have weakened
the anti-influenza immune responses. Vaccination with RD-Ad4
and Ad7 viruses may ameliorate this effect. A RD-Ad4 and Ad7
vector that is delivered to military recruits in a manner similar
to the FluMist vaccine may induce stronger anti-vector and antitransgene immune responses. In addition, studies have shown
that Ad vectors can be re-administered when delivered intranasally.27-32 Therefore, boosting with RD-Ad4 and Ad7 carrying
other pathogen genes could be used to make the vaccine even
more polyvalent.
Even though Ad7 transduction was restored in the CD46+
transgenic mice, the vaccine efficacy was actually reduced as
compared with the BALB/c vaccinated mice. The primary receptor for Ad7 has been described to be Desmoglein 2 (DSG2)
and mouse DSG2 was found to be refractory to Ad3 transduction.33 Therefore, the restored transduction in the CD46+ transgenic mice may not be representative of Ad7 receptor usage in
humans. More interestingly, the Ad7 vaccine in the CD46+ mice
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appeared to work equally well or better at lower doses, in contrast to the Ad4 vaccine. Also of interest is the fact that Ad4 and
Ad7 were equally effective at inducing anti-H1NI immunity in
BALB/c mice when vaccinated intranasally. Since, the imaging
data indicated that Ad7 did not transduce BALB/c mice very
efficiently, as compared with Ad4 and Ad5, it is likely that the
Ad7 vaccine is transducing a smaller subset of cells. This subset of
cells may be better antigen presenting cells than those transduced
by the CAR binding Ad4 vaccine. In addition, it is possible that
the higher levels of Ad7 vaccine in CD46+ mice were inducing
higher levels of damage to the lungs counteracting the vaccine
efficacy. Human CD46 is a complement regulatory protein and,
in the setting of a mouse model, may not accurately represent
its function in natural immune responses.34,35 It is possible that
while serving as one of the receptors for Ad7, CD46 may also
induce immune dysfunction in both Ad4 and Ad7 vaccinated
mice as indicated by contradictions in our imaging and vaccine
data. The CD46+ transgenic mice do provide valuable information into the complications inherent to small animal models of
human disease. The fact that increased transgene expression does
not correlate with increased vaccine efficacy contradicts logical
vaccine ideology. Recently, a human DSG2 transgenic has been
established for studying adenoviruses types 3, 7, 11, and 14. As
DSG2 has been found to be the primary high affinity receptor
for Ad7 this newly derived mouse model may better serve to evaluate human adenoviruses as vaccine vectors.36
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Figure 4. Protection by systemic intramuscular immunization in human CD46+ transgenic mice. Groups of 5 female CD46+ mice were immunized
intramuscularly with 10-fold serial dilutions of Ad4 or Ad7 expressing the centralized HA1-con hemagglutinin gene. Three weeks after immunization the
mice were challenged with 100 MLD50 of mouse-adapted influenza A/PR/8/34. Protection against weight loss and survival induced by the Ad4 vaccine is
shown in A and B, respectively. Protection against weight loss and survival induced by the Ad7 vaccine is shown in C and D, respectively. Mice that lost
25% of baseline body weight were humanely euthanized.

Figure 5. Protection by mucosal intranasal immunization in human CD46+ transgenic mice. Groups of 5 female CD46+ mice were immunized intranasally with 10-fold serial dilutions of Ad4 or Ad7 expressing the centralized HA1-con hemagglutinin gene. Three weeks after immunization the mice were
challenged with 100 MLD50 of mouse-adapted influenza A/PR/8/34. Protection against weight loss and survival induced by the Ad4 vaccine is shown
in A and B, respectively. Protection against weight loss and survival induced by the Ad7 vaccine is shown in C and D, respectively. Mice that lost 25% of
baseline body weight were humanely euthanized.
548
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While our data indicate that Ad4 and Ad7 may be suitable
vaccine vectors for translation to human use, there were several
limitations involved with our in vitro analyses. Our Ad4 vaccine, when delivered intramuscularly, induced 100% survival in
mice against a lethal heterologous influenza challenge at a dose
of 109 vp/mouse. The human vaccine dose (~105 infectious units)
used to provide protection against Ad4 and Ad7 ARD is small
compared with the dose required to protect mice from influenza
infection.37 The differences in the vaccine doses needed to protect
against influenza virus and Ad-ARD can be explained by fundamental differences in the viruses and associated disease. First,
adenoviral genomes are very stable and have an extremely low
mutation rate as compared with influenza virus.38 The stability
of the adenovirus genome ensures that the challenges are always
homologous. This is not the case for influenza virus and is the
central idea behind the use of a centralized HA gene as a broadly
reactive influenza vaccine. In this study the influenza challenge
is heterologous and the degree of mismatch between the vaccine
HA and the challenge flu HA is 8.5%. In this light, we feel that
our data indicate that protection against endemic or even pandemic influenza, would be achieved at much lower doses of vaccine, especially in the case of a homologous matched challenge
influenza. Second, vaccinated mice are challenged with a dose of
100 MLD50 of mouse-adapted influenza virus whereas Ad-ARD
infections are generally not lethal The only measure of vaccine
efficacy in this study was a lethal influenza challenge. A significant shortcoming is the lack of hemagglutination inhibition or
influenza virus neutralization data. These immune correlates
would provide valuable insight into the degree and breadth of the
induced immune responses and will be included in future studies. Although we did not do any in vitro anti-influenza analyses a
previous study evaluated the centralized HA1-con gene to induce
protection against 2009 pandemic swine flu in vivo. When vaccines were mismatched the centralized HA1-con gene was a better vaccine gene as compared with wildtype heterologous HA
genes.11
In 2010, 1.24 million people, mostly children, died from
malaria worldwide.39 Malaria infections remain a significant
health hazard to our military personnel.40,41 In a recent study by the
US Military Malaria Vaccine Program, vaccination using a DNA
prime and Ad5 boost expressing circumsporozoite protein (CSP)
and apical membrane antigen-1 (AMA1) from Plasmodium falciparum protected 27% of vaccinees against a live malaria challenge.
All of the vaccinees that had moderate to high titers of anti-Ad5
pre-existing immunity were susceptible to malaria infection.42 The
authors suggest that the use of alternative lower seroprevalent Ad
vectors and the inclusion of a third antigen should be considered a
priority for future studies. While Ad4 and Ad7 have been shown
to have moderate levels of pre-existing immunity, it is estimated
that nearly 90% of unimmunized US Army trainees would be susceptible to at least 1 of these Ad types. Studies have shown that
pre-existing immunity to Ad5 is as high as 70% in the USA and
90–100% in Asia and Africa, the prime sites for the implementation of a malaria vaccine.14,16,43 We speculate that recombinant Ad4
and Ad7 expressing P. falciparum genes may be optimal Ad vectors to create a multivalent malaria vaccine. We feel that this data
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supports the future exploration of Ad4 and Ad7 as vaccine vectors
against alternative pathogens.

Materials and Methods
Ethics statement
Female, 6–8-wk-old, BALB/c mice were obtained from
Charles River. Human CD46+ transgenic mice on a C57/
BL6 genetic background were obtained from the Mayo Clinic
toxicology core and a breeding colony was established under
the IACUC, protocol A61312. Mice were housed in the Mayo
Clinic Animal Facility under the Association for Assessment and
Accreditation of Laboratory Animal Care (AALAC) guidelines
with animal use protocols approved by the Mayo Clinic Animal
Use and Care Committee, protocol A24111). All animal experiments were performed according to the provisions of the Animal
Welfare Act, PHS Animal Welfare Policy, the principles of the
NIH Guide for the Care and Use of Laboratory Animals, and the
policies and procedures of Mayo Clinic.
Virus and DNA purification
Adenovirus type 4 strain RI-67 (ATCC VR-1572) and type
7 strain Gomen (ATCC VR-7) were purchased from ATCC.
The Ad4 and Ad7 strains were obtained from throat swabs of
California military recruits with pharyngitis in 1954.44 Final
amplification of the virus was performed in a Corning 10-cell
stack (~6300 cm2). Virus was amplified in 293 cells and purified
on 2 sequential CsCl ultracentrifuge gradients. Purified viruses
were quantitated by OD260. Viral genomic DNA (gDNA) was
purified using high-titer Ad4 and Ad7 purified virus and the
PureLink Viral RNA/DNA mini kit (Invitrogen).
Cloning of the Ad4 and Ad7 Genomes
An overlapping PCR product was amplified in order to clone
the Ad4 gDNA by homologous recombination. First, the left
and right arms of the Ad4 gDNA were amplified by PCR using
Platinum Taq Supermix High Fidelity (Invitrogen) (Fig. 6A).
Unique PacI restriction enzyme site were added just outside
of the left and right ITRs. The primers were designed to overlap and contained a unique NdeI site in between the left and
right arms of the genome (Fig. 6A). Table 1 shows the primers
used to clone the Ad4 gDNA. The Ad4-PacI-ITR acts as both
a forward and reverse primer since the sequence is an inverted
repeat. All PCR reactions were performed using Platinum Taq
Supermix High Fidelity (Invitrogen). In order to amplify the left
arm of Ad4, primers Ad4-PacI-ITR and Ad4-Recomb-R (200
mM final) were combined with 0.5 µg of Ad4 gDNA in 45 µl
of Platinum Supermix. In order to amplify the right arm of Ad4,
primers Ad4-PacI-ITR and Ad4-Recomb-F (200 mM final)
were combined with 0.5 µg of Ad7 gDNA in 45 µl of Platinum
Supermix. The following parameters were used for PCR: 95 °C
(2 min); 20 cycles of 95 °C (30s): 55 °C (30s): 68 °C (3.5 min);
68 °C (10 min); 4 °C (∞). One microliter of each PCR reaction
was combined in 45 µl of Platinum Supermix and the primer
Ad4-PacI-ITR was added to a final concentration of 400 mM.
The following parameters were used for PCR: 95 °C (2 min);
20 cycles of 95 °C (30s): 55 °C (30s): 68 °C (3.5 min); 68 °C
(10 min); 4 °C (∞). The overlapping PCR product was cloned
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Figure 6. See page 551 for legend.
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Figure 6 (See previous page). Schematic of Ad4 gDNA cloning. The right and left arms of Ad4 were amplified with primers designed to incorporate
a unique NdeI restriction site, an overlap of ~27 nucleotides and flanking PacI restriction sites (A). The 2 PCR products were fused together in a second
round of amplification (B). A schematic representation of the cloning fragment is shown (C). The cloning PCR fragment is ligated to the Kanamycin resistance gene and the pBR322 origin of replication (D). The recomb cloner plasmid was digested with NdeI and recombined with the Ad4 genomic DNA in
vitro using BJ5183 electrocompetent cells (E). The complete Ad4 genomic DNA plasmid is shown (F).

into TOPO pCR8 (Invitrogen) and confirmed by sequencing
(Fig. One B and C). The Kanamycin resistance gene (KANR) and
the pBR322 origin of replication (pBR322 ori) from pAd-Shuttle
(Stratagene) was amplified using the primers Kan ori PacI-F and
Kan ori PacI-R and the PCR product was cloned into TOPO-XL
(Invitrogen) (Table 1). The KanR and pBR322 ori were ligated to
the overlapping PCR using the PacI sites to form the cloning plasmid, pAd4-recomb-cloner (Fig. 6D). The pAd4-recomb-cloner
plasmid was digested overnight with NdeI and dephosphorylated
with Antarctic Alkaline Phosphatase (New England Biolabs).
Digested cloner plasmid and 1.0 μg of purified Ad4 gDNA were
cotransformed into BJ5183 electrocompetent cells, incubated at 37
°C with shaking for 1 h and plated on LB Kanamycin (Fig. 6E).
The plates were incubated at 37 °C overnight and small pinpoint
colonies were picked for minipreps. The miniprep DNA was confirmed by restriction enzyme digestion and transformed into XL-1
blue electrocompetent cells. The DNA was maxiprepped using
Qiagen HI Speed Maxi kits. The Ad7 genome was cloned in a similar manner with the exception that AsiSI unique restriction sites
flanked the Kanr and pBR322 oriP regions and the pAd7 recomb
cloner plasmid was linearized with PmeI (Fig. 7).
The pAd4 and pAd7 complete genome plasmid (pAd4-complete and pAd7-complete gDNA Final, respectively) were confirmed by restriction enzyme analyses (Fig. 6F and Figure 7F).
In order to confirm that the plasmids contained functional viral
gDNA, the PacI, and AsiSI digested pAd4 and pAd7 plasmids
were transfected into 293 cells using Polyfect (Qiagen) and wt
Ad4 and Ad7 virus was confirmed by plaque formation and virus
amplification.
Construction of shuttle plasmids
A series of shuttle plasmids were constructed in order to create
the Ad4 and Ad7 E3 modified viruses. Table 2 shows the primers used to create the shuttle plasmids. Each shuttle was created
using an overlapping PCR product that contained a unique AscI
restriction enzyme site (Fig. 8A). The overlapping PCR products

were amplified as previously described. The Ad4 and Ad7 E3
shuttle PCR products contained flanking PacI restriction sites.
The final PCR products were cloned into the TOPO pCR8 cloning vector (Invitrogen, Carlsbad). Each shuttle was confirmed by
sequencing.
The HA1-con and GFPLuc genes were cloned into the stratagene pShuttle-CMV plasmid (Startagene). The CMV-HA1-conPolyA and CMV-GFPLuc-PolyA expression cassettes were fused
to the FRT-Zeocin-FRT sequence by overlapping PCR. Table 3
shows the primers used to create the final PCR products. AscI
restriction sites were incorporated into the PCR primers for ligation into the shuttle plasmids. Both PCR amplified transgenes
were cloned into TOPO pCR8 (Invitrogen) and confirmed by
sequencing. Schematic representations of the 2 transgene cassettes are shown in Figure 8B.
The final shuttle plasmids were created by digesting the shuttle plasmids with AscI and dephosphorylating with Antarctic
alkaline phosphatase. The HA1-con-FZF and GFPLuc-FZF
plasmids were also digested with AscI and the plasmid backbone
was cut with MluI. The digested plasmids were ligated with T4
DNA ligase and transformed into XL-1 electrocompetent cells.
To make the recombinant Ad4 and Ad7 plasmids, the shuttle
plasmids were digested with PacI, buffer exchanged, and cotransformed with 1.0 µg of pAd4 or pAd7 in BJ5183 electrocompetent
cells. Recombinants were selected on LB containing Kanamycin
and Zeocin. Recombinants were confirmed by restriction digestion analysis. Positive recombinant clones were transformed into
XL-1 cells and maxiprepped using the Qiagen HI Speed Maxi
kits (Qiagen).
Recombinant Ad4 and Ad7 rescue and purification
The recombinant Ad4 and Ad7 genomes were released from
the plasmid backbone by digestion with PacI and AsiSI, respectively. The digested plasmids were buffer exchanged using a
Strataprep PCR purification kit (Agilent Technologies). All
transfections were performed in 6-well plates as described by

Table 1. Primers for cloning Ad4 and Ad7 gDNA
Ad4-PacI-ITR

TTAATTAACT ATCTATATAA TATACCTTA TTTTT

Ad4-Recomb-F

CAGTCATATG CTGGCCGCCG TGCATGGTCA CCTCTCAACG ACTTTCAAAT TCC

Ad4-Recomb-R

GGAATTTGAA AGTCGTTGAG AGGTGACCAT GCACGGCGGC CAGCATATGA CTG

Kan ori PacI-F

TTAATTAACG GTGTGAAATA CCGCACAGAT GCG

Kan ori PacI-R

TTAATTAAGA ATTAATTCGA TCCTGAATGG CG

Ad7-AsiSI-ITR

AAGCGATCGC CTATCTATAT AATATACCTT ATAGATGG

Ad7-Recomb-F

GAGGCCACTC TTGAGTGCCA GCGAGGTTTA AACGCGGATA CAAAGTAAAA GGCACAGGAG

Ad7-Recomb-R

CTCCTGTGCC TTTTACTTTG TATCCGCGTT TAAACCTCGC TGGCACTCAA GAGTGGCCTC

Kan ori AsiSI-F

GCGATCGCTA ATTAACATGC ATGGATCCAT ATGCGGTGTG

Kan ori AsiSI-R

GCGATCGCTT AATTAAGAAT TAATTCGATC CTGAATGGCG AATGG
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Figure 7. See page 553 for legend.
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Figure 7 (See previous page). Schematic of Ad7 gDNA cloning. The right and left arms of Ad7 were amplified with primers designed to incorporate a
unique PmeI restriction site, an overlap of ~27 nucleotides and flanking AsiSI restriction sites (A). The 2 PCR products were fused together in a second
round of amplification (B). A schematic representation of the cloning fragment is shown (C). The cloning PCR fragment is ligated to the Kanamycin resistance gene and the pBR322 origin of replication (D). The recomb cloner plasmid was digested and recombined with the Ad7 genomic DNA in vitro using
BJ5183 electrocompetent cells (E). The complete Ad7 genomic DNA plasmid is shown (F).
Table 2. Primers for Ad4 and Ad7 Shuttle Plasmids
Ad4-ΔE3-F

TTAATTAACT GACTTTGGAG AGTTCTTCCT CGC

Ad4-ΔE3-OL-R

GTAATGGGGT AAGGGGTTAG TTGATGGCGC GCCTCAGCTT TTATTATACT CAGTAC

Ad4-ΔE3-OL-F

GTACTGAGTA TAATAAAAGC TGAGGCGCGC CATCAACTAA CCCCTTACCC CATTAC

Ad4-ΔE3-R

TTAATTAATG CAATGAGTTT TCCCGAGTCG TCAAG

Ad7-ΔE3-F

TTAATTAACC TATGTCGTCA CCGACCTCAA CAG

Ad7-ΔE3-OL-R

CAAGTAAGTG ATTTTTTATT AATTTTGGCG CGCCGATGGT AATCCGCACT CCGTGGGC

Ad7-ΔE3-OL-F

GCCCACGGAG TGCGGATTAC CATCGGCGCG CCAAAATTAA TAAAAAATCA CTTACTTG

Ad7-ΔE3-R

TTAATTAAGG GTCCTAGCGA CAAACCTATA GAG

Polyfect Transfection reagent (Qiagen). Viruses were released
from infected cells by 3 freeze-thaw cycles and amplified in
sequential passages in the complementing host cell lines. The
viruses were amplified and purified as previously described for
wt Ad4 and Ad7. All viral preps were quantitated by OD260.
Infectious units of Ad4 and Ad7 expressing GFPLuc were determined by infecting 293 cells and quantitated by direct observation usning fluorescent microscopy.
In vivo luciferase activity
Luciferase activity induced by the Ad4 and Ad7 GFPLuc
expressing viruses was determined using a Lumazone imaging
system (Roper Scientific). Female BALB/c and CD46+ transgenic mice were anesthetized using ketamine/xylazine and 1010
vp of each virus was injected intramuscularly using a 27 gauge
needle into both quadriceps in 2, 25 µl injections. For intranasal immunization, the mice were anesthetized and placed on
their back. Virus was pipetted into the nares in 2 10 microliter
instillations. Twenty-four hr. post-immunization, the mice were
anasthesized with ketamine/xylazine and injected intraperitoneal
with 200 μl of d-luciferin at a concentration of 20 mg/ml in PBS.
The hair on the CD46+ transgenic mice was removed using a
Wahl trimmer in order to improve luciferase detection. The mice
were immediately placed into the Lumazone Imager and images
were captured. All images were taken with a 10 min exposure
and 4 × 4 binning using no filters and no photo-multiplication.
Data analysis was performed on each image using background
subtracted sum intensities as detected by the Lumazone Imaging
Software and graphed using PrismGraphing Software.
Immunizations and influenza challenge
Protection against influenza challenge by the HA1-con
expressing Ad4 and Ad7 vaccines was determined by serial dilution of the vaccine in BALB/c and CD46+ transgenic mice. All
immunizations and challenges were performed using ketamine/
xylazine anesthetized mice as previously described. Intranasal
and intramuscular immunizations were performed as previously
described for in vivo luciferase activity. Mice were immunized
with 10-fold dilutions of the vaccine vectors from 1010 to 107 vp/
mouse. Three weeks after immunization the mice were challenged
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with 100 MLD50 of mouse-adapted A/PR/8/34 influenza virus
as previously described.11 The mice were observed for 2 wk for
signs of disease, weight loss, and death. Mice that lost more than
25% of baseline body weight were humanely euthanized.
Ad neutralization assay
Ad7 neutralization was performed as previously described.45
Briefly, serial dilutions of plasma were made in cDMEM and
incubated in triplicate for 1 h at 37 °C with 500 vp of Ad7 vector
expressing the eGFP-luciferase fusion gene. The resulting solution was added to A549 cells in a black 96 well plate for 24 h and
luciferase activity was measured. Data are expressed as the mean
titer that reduced Ad7 luciferase activity by ≥90%.
In vitro luciferase activity
293 cells were infected with 104 vp/cell of either Ad4 or
Ad7 virus expressing the GFPLuc gene. The luciferase activity
was determined 24 h post-infection by lysing the cells with the
reporter lysis 5X buffer. Luciferase activity was detected using
the luciferase assay reagent (LAR) (Promega) as described by the
manufacturer protocol. Briefly, 25 µl of 5X lysis buffer was added
to each well of a 96-well plate and mixed. Then 50 µl of LAR was
added and the luciferase activity was measured using a Beckman
Coulter DTX 880 microplate reader.
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Figure 8. Construction of E3 shuttle plasmids and transgenes. In order to create replication-competent vectors, the nonessential E3 were genes replaced
with either a HA1-con expression cassette or a GFPLuc fusion gene. The PCR products that were used to create the shuttle plasmids for Ad4 and Ad7
are shown (A). Both of the overlapping PCR products were designed to flank the E3 genes and contained unique AscI sites. The AscI flanked transgene
expression cassettes are shown (B). The CMV expression cassettes were fused to a FRT flanked zeocin gene for selection of recombinants and ultimate
removal by FLP recombinase.
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Table 3. Primers for Transgenes
CMV-AscI-F

GGCGCGCCCG CGTTACATAA CTTACGGTAA ATGGCC

Ad-GL-FZF-R

GCTAGCGATA TCGCGGCCGC GAGCTCATAA GATACATTGA TGAGTTTGGA CAAACCACAA CTAGAATGCA GTG

Ad-GL-FZF-F

CACTGCATTC TAGTTGTGGT TTGTCCAAAC TCATCAATGT ATCTTATGAG CTCGCGGCCG CGATATCGCT AGC

FZF-AscI-R

GGCGCGCCGA TCCGCGTTGC CTGCAGGTCG ACTCTA
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Supplemental Figure 1. In vitro luciferase activity and infectious units of
Ad4 and Ad7 viruses. In order to determine if both Ad vaccines were capable
of expressing equivalent levels of transgene protein we measure luciferase
activity in Ad4 and Ad7 virus infected 293 cells (A). In order to determine the
virus particle to infectious unit ratios, the Ad4 and Ad7 virus transduction of 293
cells in vitro was determined.

293 cells were incubated with the viruses

expressing GFPLuc and quantitated by direct visualization using fluorescent
microscopy (B). Error bars indicate standard deviation.
Supplemental Figure 2. Ad7 in vivo induced neutralization. BALB/s mice
were immunized with 1010 vp/mouse of Ad7 expressing GFPLuc. Sera was
collected on day 21 post-immunization and Ad7 neutralizing antibodies were
measured. The mean titer that inhibited 90% of Ad7 luciferase expression is
shown. Error bars indicate standard deviation (n = 5).	
  

